biostudies-literatureUnknown13(1)Sahu A<h4>Purpose and background</h4>Isocitrate dehydrogenase (IDH) mutation and O-6 methyl guanine methyl transferase (MGMT) methylation are surrogate biomarkers of improved survival in gliomas. This study aims at studying the ability of semantic magnetic resonance imaging (MRI) features to predict the IDH mutation status confirmed by the gold standard molecular tests.<h4>Methods</h4>The MRI of 148 patients were reviewed for various imaging parameters based on the Visually AcceSAble Rembrandt Images (VASARI) study. Their IDH status was determined using immunohistochemistry (IHC). Fisher's exact or chi-square tests for univariate and logistic regression for multivariate analysis were used.<h4>Results</h4>Parameters such as mild and patchy enhancement, minimal edema, necrosis &lt; 25%, presence oJournal of personalized medicine72https://www.ebi.ac.uk/biostudies/studies/S-EPMC9865247biostudies-literatureMultiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas.PMC9865247Sahay AChoudhari AKGupta TMoiyadi AAShetty PPatnam NGDesai SMPratishad PChatterjee ASahu AGoda JSEpari SDasgupta AMathew RfalseMultiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas.<h4>Purpose and background</h4>Isocitrate dehydrogenase (IDH) mutation and O-6 methyl guanine methyl transferase (MGMT) methylation are surrogate biomarkers of improved survival in gliomas. This study aims at studying the ability of semantic magnetic resonance imaging (MRI) features to predict the IDH mutation status confirmed by the gold standard molecular tests.<h4>Methods</h4>The MRI of 148 patients were reviewed for various imaging parameters based on the Visually AcceSAble Rembrandt Images (VASARI) study. Their IDH status was determined using immunohistochemistry (IHC). Fisher's exact or chi-square tests for univariate and logistic regression for multivariate analysis were used.<h4>Results</h4>Parameters such as mild and patchy enhancement, minimal edema, necrosis &lt; 25%, presence o2022-01-01T00:00:00Z2022 Dec2025-04-22T01:06:38.678Z2025-04-05T19:51:53.882ZS-EPMC98652473667573310.3390/jpm13010072